Momenta to pay $35 million to resolve enoxaparin antitrust suit
MLex Summary: Momenta Pharmaceuticals said it has reached an agreement to pay $35 million to resolve a class action alleging it worked with Sandoz to prevent a generic rival from offering...To view the full article, register now.
Already a subscriber? Click here to view full article